Learn more At first glance, Eli Lilly's (NYSE: LLY) current share price of $903 feels like a psychological barrier. Most ...

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

Why Wall Street loves Lilly. So what does this Wall Street analyst like about Lilly? Yesterday, Eli Lilly announced it will ...

Eli Lilly and Company (NYSE:LLY) is one of the 8 Best Beginner Stocks to Buy Right Now. On April 15, 2026, Eli Lilly and ...

Parkland School Board members expressed deep skepticism about a proposed tax break for Eli Lilly, using their Tuesday ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is ...

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

Eli Lilly is upgraded to Buy after a 13% pullback and strong Q4 guidance, with potential for 25% topline growth in 2026.

By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly will buy privately held biotech firm Kelonia Therapeutics ...

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

Eli Lilly (NYSE: LLY) is reportedly in talks to acquire cancer biotech Kelonia Therapeutics in a deal that could be worth ...